Evaluation of the GORE® C3 Delivery System Module
This trial is active, not recruiting.
|Condition||aortic aneurysm, abdominal|
|Treatment||stent graft (excluder)|
|Sponsor||W.L.Gore & Associates|
|Start date||January 2011|
|End date||November 2012|
|Trial size||400 participants|
|Trial identifier||NCT01398332, GRT 10-12|
This is an observational Registry designed to obtain early data on the use of the GORE® EXCLUDER® AAA Endoprosthesis with C3 Delivery System.
Indication for aortic endovascular stent graft repair
Evaluate procedural outcomes for the GORE® EXCLUDER® AAA Endoprosthesis with C3 Delivery System when used in accordance with the standard medical practice at each participating hospital.
time frame: Up to 10 Years
Male or female participants of any age.
Inclusion Criteria: 1. Minimum age required by local regulations (as applicable) 2. Indication for aortic endovascular stent graft repair as determined by the treating physician (refer to current Instructions for Use of the GORE® EXCLUDER® AAA Endoprosthesis with C3 Delivery System)
|Official title||Global Registry for Endovascular Aortic Treatment(GREAT)|
|Principal investigator||Eric Verhoeven, MD|
|Description||This is a retrospective and prospective observational cohort Registry designed to obtain data on the use of the GORE® EXCLUDER® AAA Endoprosthesis with C3 Delivery System. Patient and device performance outcomes will be collected during treatment and throughout all post-treatment visits, including follow-up extending up to 10 years.|
Call for more information